association between empirical dietary inflammatory pattern score and the risk of colorectal cancer categorized by the presence of F nucleatum in the tumor. The investigators found that high empirical dietary inflammatory pattern scores were associated with higher risk of F nucleatum-positive colorectal tumors (hazard ratio, 1.63; 95% CI, 1.03-2.58) but not F nucleatum-negative tumors. This association was stronger for proximal colon tumors as compared to distal tumors and did not appear to differ based on tumor MSI status. This study suggests an important role of diet and gut microbiota in colorectal cancer development and further supports the benefits of a low inflammatory diet.
See page 1622.
Efficacy of Granulocyte Colony Stimulating
Factor and N-acetyl Cysteine Therapies in Patients With Severe Alcoholic Hepatitis G ranulocyte colony stimulating factor (GCSF) has shown early promise as an effective therapy for alcoholic hepatitis (AH). Singh et al, 4 hypothesized that the combination of GCSF with N-acetyl cysteine (NAC) would be better than GCSF alone or pentoxyifylline alone in the management of acute severe AH. In this issue of Clinical Gastroenterology & Hepatology, Singh et al, 4 reported results from a randomized controlled trial that examined the combination of GCSF with N-acetyl cysteine (NAC) versus GCSF or pentoxyifylline alone in the management of acute severe AH. The primary endpoint was survival at 90 days; secondary endpoints included measurement of hematopoietic stem cells in peripheral blood, improvement in clinical scores such as Model for End-Stage Liver Disease and adverse effects of GCSF and NAC. In 57 patients with severe AH, improvement in clinical parameters and 90-day survival was better in the GCSF and combination groups as compared to the standard medical therapy group. However, there was no added benefit with the addition of NAC to GCSF. Stem cells increased in the GCSF and combination therapy groups compared to baseline but not in the SMT group. GCSF and combination therapy were well tolerated in all patients. The investigators conclude that GCSF therapy with or without NAC may be a safe and effective option to treat severe AH.
